NCT02437890: A reported trial by Ablynx, a Sanofi company
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT02437890 |
|---|---|
| Title | A Phase II Multicenter, Randomized, Double-blind, Placebo Controlled, Dose-range Finding Study to Evaluate the Safety and Efficacy of ALX-0061 Administered Subcutaneously in Subjects With Moderate to Severe Active Systemic Lupus Erythematosus |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | July 31, 2015 |
| Completion date | Jan. 31, 2018 |
| Required reporting date | Jan. 31, 2021, midnight |
| Actual reporting date | Nov. 16, 2018 |
| Date last checked at ClinicalTrials.gov | June 19, 2026 |
| Days late | None |